New startup ideas · Health and bio · Healthcare and bio
startup idea
Cytebench
A cGMP cell therapy production pod inside community oncology clinics, with an open protocol API.
Cytebench builds a closed, room-temperature benchtop system that manufactures autologous cell therapy doses at the point of care, and exposes the run as an API so therapy developers can publish validated protocols onto it.
- Infrastructure and APIs
- Small business
- $10-100B market
- Platform others build on
- US first
3/5
venture judge
8
similar startups, last 2 years (86 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$1,500 · 6 weeks · 15 prospects
For about $1,500 and 6 weeks, prove that community oncology practices will put down $1,000 each to host a point-of-care cell therapy pod and that at least one sponsor will sign for a funded protocol slot, before any hardware exists.
1Focus group: who and where
Practice administrator or managing physician at an independent community oncology practice with 5-20 physicians and an in-house infusion suite, currently referring 2 or more cell therapy candidates per month out to an academic center 100+ miles away and losing the patient relationship and the infusion revenue
where to find 15 · Community Oncology Alliance (COA) member practices and the COA Community Oncology Conference network; LinkedIn Sales Navigator filtered to 'practice administrator' or 'executive director' at oncology practices with 11-200 employees
2Sell first, build later
To practices: a place in the first six-site cohort hosting a sponsor-funded cell therapy protocol, pod installed and founding team on site for the first runs, target first run within 18 months, at a locked per-run fee. To sponsors: a feasibility study with 3 named, letter-committed community practices and a defined site-amendment pathway, starting within 2 quarters.
the ask · $1,000 refundable reservation per practice now, with a locked $4,000 per-run fee at launch; sponsor feasibility study scoped at $50,000 to $150,000, LOI first, invoiced at contract
a real yes · Real yeses are a paid $1,000 reservation with a signed reservation agreement, and a sponsor LOI naming the program, the budget range, and a start quarter. Enthusiastic physicians, unsigned 'we would host it' emails, and sponsor meetings that end in 'keep us posted' do not count.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Fifteen referral-loss discovery calls
$250 · 14 days
Book 15 calls with practice administrators from the COA and Sales Navigator lists using one question: 'How many patients did you refer out for CAR-T or other cell therapy last quarter, and what did each referral cost the practice?' Walk them through a clickable render of the pod, the per-run economics from the practice's side, and the investigational site pathway. Founder runs all calls and logs monthly referral volume and infusion suite capacity.
keep going if · 10 of 15 report 2+ cell therapy referrals out per month and say they would host a pod under a sponsor-funded protocol
2. Sponsor protocol slot offer
$300 · 21 days
Send a one-page offer to 10 US autologous cell therapy developers at Series A-C, sourced from the Alliance for Regenerative Medicine member list and LinkedIn: a funded feasibility study placing their protocol in 3 named community practices (from experiment 1) under an investigational manufacturing site amendment, with letters from those practices attached. Ask for a 30-minute scoping call, then a signed LOI with a study budget range and a target start quarter.
keep going if · 3 of 10 sponsors take the scoping call and 1 signs an LOI with a dated start quarter and named program
3. Thousand-dollar pod reservations
$400 · 21 days
Return to the 10 warm practices with a reservation page: a Stripe Payment Link for a $1,000 fully refundable deposit that reserves a pod in the first six-site cohort, a locked per-run fee, and first access to the sponsor protocol from experiment 2. The administrator signs a one-page reservation agreement on DocuSign; the founder walks each one through it live on a call.
keep going if · 4 of 10 practices pay the $1,000 reservation
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$1,000
per prospect, refundable
how · A refundable reservation via a Stripe Payment Link plus a one-page reservation agreement signed by the practice administrator or managing partner; the sponsor side is collected as a signed LOI with a dated start quarter, since sponsors cannot credibly pay before a scoped protocol and quality agreement exist set up: Stripe Payment Links ↗
what it reserves · A pod in the first six-site cohort, a locked $4,000 per-run fee for the first two years, and first access to the launch sponsor's protocol
refund · Fully refundable on request at any time before installation, and refunded automatically if the pod is not installed at the practice within 24 months.
target · 4 paid reservations from 15 practices and 1 signed sponsor LOI within 45 days
Go: build it if
4 practices pay $1,000 each, 10 of 15 confirm 2+ monthly referrals lost, and 1 sponsor signs a dated LOI: raise on this evidence and start the regulatory and hardware work.
Kill: stop if
Fewer than half the practices report meaningful cell therapy referral volume, or 0 reservations from 10 asks, or 0 sponsor LOIs from 10 approaches: the two-sided demand is not there yet, stop before touching hardware.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
67
Idea Score, 0-100 · raw 41.0 x 1.64
Active
competition: more crowded than 65% of ideas · headwind x0.67
+4.9
government priorities, secondary (184 matching grants)
Trend
53
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)21
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
52
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain25
100x potential
56
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis67
- Moat axis20
- Neighbours still alive47
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were cgmp, cell, therapy, production, pod, community, oncology, builds.
The idea in full
- What
- Cytebench builds a closed, room-temperature benchtop system that manufactures autologous cell therapy doses at the point of care, and exposes the run as an API so therapy developers can publish validated protocols onto it. The buyers are independent community oncology practices and small infusion centers that cannot ship patients to an academic center. Clinics pay per run; sponsors pay for protocol slots, which is the platform layer others build on.
- Why now
- Gamgee (yc S26) is pitching scalable personalised cancer treatment and FinalDose (yc X26) a programmable DNA cancer drug in the same two cohorts, while Ambrosia Biosciences took a $100M Series B on 2026-03-31, so the therapies exist and the bottleneck has moved to where doses get made.
- Wedge: first customer and entry point
- Six community oncology practices already running biologic infusions, starting with a single sponsor-funded protocol under an investigational manufacturing site amendment, with the founding team on site for the first runs.
- Path to 100x
- Cell and gene therapy manufacturing is a $10-100B market currently locked to a handful of centralized facilities, and moving production to the clinic collapses the cost and the vein-to-vein time that limits patient volume. If sponsors publish protocols onto the installed base to reach community patients, the pod becomes the distribution channel for an entire therapy class.
- Ceiling
- There is no moat yet: a large contract manufacturer or an instrument maker can copy the pod once the regulatory path is proven, and hardware alone does not hold the sponsors.
- Closest real companies, as the generator saw them
- Ruma Care (yc W26) builds the operations stack for biologic infusion clinics but stays in software; AbInitio Bio (yc X26) is an intelligence layer for drug manufacturing, not the machine. Cytebench is the physical production unit those layers would sit on top of.
- Main risk
- FDA treats every clinic as a separate manufacturing site requiring its own inspection, and the per-site regulatory cost never amortizes.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
A $10-100B category-defining distribution channel, but the card admits no moat and FDA may inspect every clinic as a separate site.
Bootstrapper
1/5
FDA may inspect every clinic as a separate manufacturing site, so per-site regulatory cost never amortizes on a capital-heavy pod.
Operator
2/5
Community oncology practices must become inspected manufacturing sites to benefit, a workflow change no clinic owner wants at per-site FDA cost.
Technologist
5/5
A closed room-temperature benchtop system manufacturing autologous doses at the point of care is among the hardest builds here, moat or not.
Risk
1/5
No moat plus FDA likely inspecting each of six community oncology clinics as a separate manufacturing site, with sponsors free to leave anytime.
trends
2/5
Point-of-care cell therapy pods cite funded therapies but no FDA change dated 2025-2026, and the card admits per-site inspection economics are unresolved.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (cgmp, cell, therapy, production, pod, community, oncology, builds): 86 all-time, 8 from the last two years. Same matching as Idea Check.
Supercharging existing cancer therapies.
Using protein coupling to build new therapies
Living therapies for pets first, and their people next
Core Biogenesis is a biotechnology company building next-generation recombinant protein production technologies.
Building the Sobriety Platform for the future of Superintelligence. 🌻
Robotic pitstops for self-driving cars
OmniSpirant develops regenerative gene therapies with game changing innovation in respiratory medicine and oncology.
We Handle AI. You Direct Films.
Serenity Power drives the clean energy transition using advanced Solid Oxide Fuel Cell (SOFC) technology, focusing on decarbonizing complex industries.
Genomate Health is a digital health company that develops computational (AI) solutions for personalized medicine.
Turn the web into structured data
To move goods more like we do information.
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- Personalized Diabetes Management through iPSC-Derived β-cells: A Tailored Approach for Improving Treatment Efficacy in Economically Vulnerable Populationsawardhigh relevance
NIH / NIDDK · SBIR phase I · $307K · posted 2026-08-15
- VivoSphere as an oncology platform for colorectal cancer modeling and drug screeningawardhigh relevance
NIH / NCI · SBIR phase II · $350K · posted 2026-08-01
- Developing a gene therapy-based solution for early intervention in age related macular degeneration (AMD) to prevent disease progressionawardhigh relevance
NIH / NEI · SBIR phase II · $1M · posted 2026-08-01
NIH / NIDDK · STTR phase I · $350K · posted 2026-07-01
- Quantifying peripheral blood antigen-specific memory B cells as a new biomarker in patients with PLA2R-associated membranous nephropathyawardhigh relevance
NIH / NIDDK · SBIR phase I · $305K · posted 2025-09-15
NIH / NICHD · SBIR phase II · $1M · posted 2025-09-15
NIH / NCI · STTR phase I · $400K · posted 2025-09-02
NIH / NCI · STTR phase I · $305K · posted 2025-09-01
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Small business
- Business model
- Infrastructure and APIs
- Path to 100x
- Platform others build on
- Market size
- $10-100B market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Partners and channels
- Moat
- No moat yet
- Geography
- US first
- Regulation
- Heavily regulated
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-22 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.